Results 151 to 160 of about 75,915 (258)
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1117-1125, April 2026.Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1177-1185, April 2026.Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert +5 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 942-952, April 2026.Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens +10 more
wiley +1 more source
CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy
Регуляторные исследования и экспертиза лекарственных средств, 2018 The article reviews existing methods of determining CYP3A4 isoenzyme activity. The authors assess the significance of CYP3A4 activity determination and the applicability of these methods in clinical practice to adjust drugs doses and minimize risks of ...
E. A. Egorenkov +4 more
doaj
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1095-1104, April 2026.Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by ...
Pablo Salcedo +11 more
wiley +1 more source
Drug Development Research, Volume 87, Issue 2, April 2026.ABSTRACT The roots of the climbing shrub Cryptolepis sanguinolenta are traditionally used in West Africa for the treatment of malaria. The principal constituent, cryptolepine (1), has been shown to have antimalarial activity but there are concerns regarding its toxicity on account of its DNA‐intercalating property.
Elodie Chenu +7 more
wiley +1 more source